I'ROM GROUP CO., LTD. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,754 JPY | -2.56% |
|
-3.84% | -12.69% |
| 2023 | I'rom Group Co., Ltd. Reports Earnings Results for the Full Year Ended March 31, 2023 | CI |
| 2022 | Lupin Ties Up with I'rom Group to Commercialize Denosumab in Japan | MT |
| Sales 2022 | 15.69B 102M | Sales 2023 | 18.35B 119M | Capitalization | 22.91B 148M |
|---|---|---|---|---|---|
| Net income 2022 | 1.96B 12.71M | Net income 2023 | 2.54B 16.47M | EV / Sales 2022 | 1.93 x |
| Net Debt 2022 | 6.99B 45.31M | Net Debt 2023 | 9.12B 59.12M | EV / Sales 2023 | 1.75 x |
| P/E ratio 2022 |
11.9
x | P/E ratio 2023 |
9.01
x | Employees | - |
| Yield 2022 |
2.08% | Yield 2023 |
2.64% | Free-Float | 49.04% |
More Fundamentals
* Assessed data
More news
| 1 day | -2.56% | ||
| 1 week | -3.84% | ||
| Current month | -7.15% | ||
| 1 month | -7.78% | ||
| 3 months | -12.61% | ||
| 6 months | +4.59% | ||
| Current year | -12.69% |
1 week
1 750.00
1 828.00
1 month
1 750.001 950.00
Current year
1 750.002 087.00
1 year
1 602.002 087.00
3 years
1 410.002 751.00
5 years
880.003 870.00
10 years
639.003 870.00
| Managers | Title | Age | Since |
|---|---|---|---|
Toyotaka Mori
PSD | President | 65 | 97-04-08 |
Hiroaki Inukai
ADM | Chief Administrative Officer | 57 | 10-10-31 |
Naomi Ninagawa
BRD | Director/Board Member | - | 97-03-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Toyotaka Mori
PSD | President | 65 | 97-04-08 |
Shuichi Kojima
BRD | Director/Board Member | 55 | 05-04-30 |
Kiyoshi Watanabe
BRD | Director/Board Member | 66 | 04-12-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.02% | 19 M€ | +1.17% | ||
| 0.00% | 18 M€ | +16.15% | - | |
| 0.00% | 20,721 M€ | +10.75% | - | |
| 0.00% | 144,586 M€ | +11.70% | ||
| 0.00% | 66,066 M€ | +11.66% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-18 | 1,754 | -2.56% | 26 300 |
| 24-04-18 | 1,800 | +0.90% | 10,600 |
| 24-04-17 | 1,784 | -1.00% | 32,800 |
| 24-04-16 | 1,802 | -1.15% | 41,400 |
| 24-04-15 | 1,823 | -0.05% | 12,400 |
Delayed Quote Japan Exchange, April 18, 2024 at 11:31 pm EDT
More quotes
I'rom Group Co.,Ltd. is engaged in medical fields such as regenerative medicine and gene discovery. The Company operates through four business segments. The SMO segment provides support services for contracting or substituting a part of the work related to conducting clinical trials from the conducting medical institution. The CRO segment provides all or part of clinical trial operations from pharmaceutical companies and others. The Advanced Medicinal Treatment segment is engaged in the development of gene therapy products, the development, manufacture and sale of products in the field of regenerative medicine based on iPS cells related technologies, as well as the provision of contract manufacture services. The Medical Support segment provides general and comprehensive support for medical business management, such as setting up and renting clinic malls, selling products and related services. The Company also provides business utilizing IT infrastructure.
Calendar
2024-05-12
- Q4 2024 Earnings Release
| 1st Jan change | Capi. | |
|---|---|---|
| -12.69% | 140M | |
| -18.69% | 8.01B | |
| +36.93% | 3.52B | |
| -26.72% | 2.98B | |
| -7.36% | 2.48B | |
| -12.92% | 2.31B | |
| -14.89% | 1.75B | |
| -23.12% | 1.45B | |
| -39.19% | 1.27B | |
| -10.58% | 1.08B |
- Stock Market
- Equities
- 2372 Stock
